Patents Assigned to Elan Pharmaceuticals, Inc.
  • Humanized antibodies that recognize beta amyloid peptide
    Publication number: 20040087777
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Application
    Filed: March 12, 2003
    Publication date: May 6, 2004
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Guriq Basi, Jose Saldanha, Ted Yednock
  • Humanized antibodies that recognize beta amyloid peptide
    Publication number: 20040082762
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Application
    Filed: March 12, 2003
    Publication date: April 29, 2004
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Guriq Basi, Jose Saldanha
  • D and L etherlipid stereoisomers and liposomes
    Publication number: 20040047903
    Abstract: A liposome having a lipid bilayer, where the lipid bilayer includes either the L or D stereoisomer of an ether lipid or a non-equal mixture of both. Most preferably the liposome also comprises (a) an underivatized phosphatidylcholine; (b) a sterol; (c) about 5-20 mole % of a phosphatidylethanolamine linked to a dicarboxylic acid at the ethanolamine group of the phosphatidylethanolamine, and (d) greater than about 10 mole % to less than about 30 mole % of either the L or D stereoisomer of an ether lipid. The liposome may be used as an anti-cancer or anti-inflammatory agent.
    Type: Application
    Filed: August 26, 2003
    Publication date: March 11, 2004
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: Imran Ahmed, Eric Mayhew, Andrew Janoff
  • Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6696438
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: February 24, 2004
    Assignees: Elan Pharmaceuticals, Inc., Eli Lilly & Company
    Inventors: James E. Audia, Bruce A. Dressman, Qing Shi
  • Phenylalanine derivatives as alpha 4 integrin inhibitors
    Patent number: 6689781
    Abstract: Disclosed are a series of phenylalanine derivatives, to compositions containing them, to processes for their preparation, and to their use in medicine.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: February 10, 2004
    Assignees: Elan Pharmaceuticals, Inc., American Home Products Corporation
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Susan Ashwell, Gregory S. Welmaker, Anthony Kreft, Dimitrios Sarantakis, Darren B. Dressen, Francine S. Grant, Christopher Semko, Ying-Zi Xu
  • Methods of using metaxalone in the treatment of musculoskeletal conditions
    Patent number: 6683102
    Abstract: A method of increasing the bioavailability of metaxalone by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: January 27, 2004
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Michael Scaife, Jaymin Shah
  • D and L etherlipid stereoisomers and liposomes
    Patent number: 6667053
    Abstract: A liposome having a lipid bilayer, where the lipid bilayer includes either the L or D stereoisomer of an ether lipid or a non-equal mixture of both. Most preferably the liposome also comprises (a) an underivatized phosphatidylcholine; (b) a sterol; (c) about 5-20 mole % of a phosphatidylethanolamine linked to a dicarboxylic acid at the ethanolamine group of the phosphatidylethanolamine, and (d) greater than about 10 mole % to less than about 30 mole % of either the L or D stereoisomer of an ether lipid. The liposome may be used as an anti-cancer or anti-inflammatory agent.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: December 23, 2003
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Imran Ahmad, Eric Mayhew, Andrew Janoff
  • Selecting compounds to reduce inflammation associated with Alzheimer's disease
    Patent number: 6664442
    Abstract: The invention includes identification of specific markers, the elevation of which in central nervous tissue is associated with Alzheimer's Disease. The invention also includes improved assay methods for selecting compounds useful in reducing or preventing onset of the pathology associated with Alzheimer's Disease.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: December 16, 2003
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Lisa C. McConlogue, Kate D. Games, Theodore A. Yednock, Tan Hua, Elizabeth Messersmith, Frederique Bard
  • Voltage-gated calcium channel antagonist and method
    Patent number: 6653460
    Abstract: A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: November 25, 2003
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Robert Newcomb, Andrew L. Palma, Balazs G. Szoke, Katalin Tarczy-Hornoch, William F. Hopkins, Ruth L. Cong, George P. Miljanich, Robin Dean, Laszlo Nadasdi, Laszlo Urge, Stephen Scott Bowersox
  • &bgr;-secretase enzyme compositions and methods
    Patent number: 6627739
    Abstract: Disclosed are various forms of an active, isolated &bgr;-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (&bgr;-APPwt and &bgr;-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate &bgr;-secretase. Inhibitors of &bgr;-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 30, 2003
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: John P. Anderson, Guriqbal Basi, Minh Tam Doan, Normand Frigon, Varghese John, Michael Power, Sukanto Sinha, Gwen Tatsuno, Jay Tung, Shuwen Wang, Lisa McConlogue
  • Method for pulmonary and oral delivery of pharmaceuticals
    Patent number: 6616914
    Abstract: In a powder formulation for use in a dry powder inhaler, a pharmaceutical acts as its own carrier, so that use of lactose or other excipients are not needed. The dry powder formulation has a single active pharmaceutical compound having two major populations in particle size distribution: microfine particles of the active pharmaceutical, of 1-10 microns in diameter, and larger carrier particles, also of the active pharmaceutical compound. The carrier particles provide a long acting, delayed onset, and optionally therapeutic effect via the GI tract, while the microfine particles provide a fast onset effect via the lung.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: September 9, 2003
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Gary Ward, Robert Schultz
  • Humanized antibodies that recognize beta amyloid peptide
    Publication number: 20030165496
    Abstract: The invention provides improves agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Application
    Filed: December 6, 2001
    Publication date: September 4, 2003
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Guriq Basi, Jose Saldanha, Ted Yednock
  • Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor
    Patent number: 6610827
    Abstract: The present invention provides novel potassium channel subunits (denoted Kv-SL1 and Kv-SL2, and collectively as Kv-SL) and polynucleotides which identify and encode them. The invention also provides expression vectors and host cells comprising nucleic acid sequence encoding Kv-SL. The invention also provides antibodies of Kv-SL and methods of diagnosing and treating diseases associated with expression of Kv-SL, and screening assays employing the protein, nucleotide, and antibody compositions.
    Type: Grant
    Filed: October 28, 1998
    Date of Patent: August 26, 2003
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: John R. Forsayeth, Byron Zhao, Raymond A. Chavez
  • Method of controlling the size of liposomes
    Patent number: 6596305
    Abstract: A process for producing liposomes having a desired mean particle size wherein the desired mean particle size is obtained by varying the initial organic solvent concentration.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: July 22, 2003
    Assignee: Elan Pharmaceuticals, Inc.
    Inventor: Laura M. Edgerly-Plug
  • Transgenic rodents harboring APP allele having Swedish mutation
    Patent number: 6586656
    Abstract: The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.
    Type: Grant
    Filed: April 18, 2001
    Date of Patent: July 1, 2003
    Assignees: Elan Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Lisa McLonlogue, Jun Zhao, Sukanto Sinha
  • Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6552013
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: April 22, 2003
    Assignees: Elan Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: James E. Audia, Warren J. Porter, Richard C. Thompson, Stephen C. Wilkie, Douglas R. Stack, Qing Shi
  • &agr;aminocetic acid derivatives- &agr;4&bgr;7 receptor antagonists
    Patent number: 6545160
    Abstract: Disclosed are compounds which bind &agr;4&bgr;7 integrin. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by &agr;4&bgr;7 integrin. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: April 8, 2003
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett
  • Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6545003
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: April 8, 2003
    Assignees: Elan Pharmaceuticals, Inc., American Home Products
    Inventors: Francine S. Grant, Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett
  • Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6528505
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: March 4, 2003
    Assignees: Elan Pharmaceuticals, Inc., Eli Lilly & Company
    Inventors: James E. Audia, Bruce A. Dressman, Qing Shi
  • Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6525026
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: February 25, 2003
    Assignees: Elan Pharmaceuticals, Inc., American Home Products Corporation
    Inventors: Eugene D. Thorsett, Christopher M. Semko, Dimitrios Sarantakis, Michael A. Pleiss, Anthony Kreft, Andrei W. Konradi, Francine S. Grant, Darren B. Dressen, Susan Ashwell, Reinhardt Bernhard Baudy, Louis John Lombardo